Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gyre Therapeutics, Inc. - Common Stock (NQ:GYRE)

8.390 +0.180 (+2.19%)
Streaming Delayed Price Updated: 12:48 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gyre Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
From Gyre Therapeutics Inc.
Via GlobeNewswire
BioMedNewsBreaks — Gyre Therapeutics (NASDAQ: GYRE) Advances Toward China Approval and Expands Clinical Pipeline With Hydronidone
Via Investor Brand Network
News headline image
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Net Income of $3.7 million; reaffirms Full-Year Revenue Guidance of $118–$128 million 
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
From Gyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
From Gyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
From Gyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
From Gyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Gyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
From Gyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
From Gyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
From Gyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
From Gyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
From Gyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
From Gyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
From Gyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Gyre Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.